

CLAIMS:

5 1. An isolated endostatin protein, wherein the protein has
an amino acid sequence selected from the group consisting of SEQ
ID NO:3 and SEQ ID NO:5.

10 2. The endostatin protein of Claim 1 having an amino
acid sequence of SEQ ID NO:3.

15 3. The endostatin protein of Claim 1 having an amino
acid sequence of SEQ ID NO:5.

20 4. The endostatin protein of Claim 1 made by a process
comprising, recombinantly producing the protein of Claim 1 in a
recombinant expression system, and isolating the recombinantly
produced protein in its un-refolded form.

25 5. The endostatin protein of Claim 4, wherein the
endostatin protein has an amino acid sequence of SEQ ID NO:3.

30 6. The endostatin protein of Claim 4, wherein the
endostatin protein has an amino acid sequence of SEQ ID NO:5.

25 7. The endostatin protein of Claim 4, wherein the
recombinant expression system is selected from the group
consisting of bacterial expression systems, yeast expression
systems and insect viral expression systems.

30 8. The endostatin protein of Claim 7, wherein the
recombinant expression system is *E. coli*, *Pichia*, or baculovirus.

35 9. An isolated nucleic acid molecule having a sequence
encoding an endostatin protein, wherein the nucleic acid sequence

is selected from the group consisting of SEQ ID NO:4 and SEQ ID NO:6.

5 10. The isolated nucleic acid molecule of Claim 9 having the sequence of SEQ ID NO:4.

11. The isolated nucleic acid molecule of Claim 9 having the sequence of SEQ ID NO:6.

10 12. The composition of Claim 6, further comprising, a vector containing the nucleic acid sequence encoding endostatin protein, wherein the vector is capable of expressing an endostatin protein when present in a cell.

15 13. The composition of Claim 9, wherein the nucleic acid has a sequence of SEQ ID NO:4.

14. The composition of Claim 9, wherein the nucleic acid has a sequence of SEQ ID NO:6.

20 15. The endostatin protein of Claim 1, further comprising a pharmaceutically acceptable excipient.

25 16. The endostatin protein of Claim 15, wherein the endostatin protein has a sequence of SEQ ID NO:3.

17. The endostatin protein of Claim 15, wherein the endostatin protein has a sequence of SEQ ID NO:5.

30 18. The composition of Claim 15, wherein the composition provides a sustained release of the endostatin protein for a period of at least 8 hours.

20201422-24442

19. The endostatin protein of Claim 15, wherein the protein is administered to an individual for the treatment of an angiogenesis-related disease.

5 20. The endostatin protein of Claim 15, wherein the angiogenesis-related disease is an angiogenesis-dependent cancer.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100